243 related articles for article (PubMed ID: 17672443)
21. Effects of petrosaspongiolide M, a novel phospholipase A2 inhibitor, on acute and chronic inflammation.
Garcia-Pastor P; Randazzo A; Gomez-Paloma L; Alcaraz MJ; Paya M
J Pharmacol Exp Ther; 1999 Apr; 289(1):166-72. PubMed ID: 10087000
[TBL] [Abstract][Full Text] [Related]
22. PGE2 release is independent of upregulation of Group V phospholipase A2 during long-term stimulation of P388D1 cells with LPS.
Kessen UA; Schaloske RH; Stephens DL; Killermann Lucas K; Dennis EA
J Lipid Res; 2005 Nov; 46(11):2488-96. PubMed ID: 16150819
[TBL] [Abstract][Full Text] [Related]
23. Pharmacology of LY315920/S-5920, [[3-(aminooxoacetyl)-2-ethyl-1- (phenylmethyl)-1H-indol-4-yl]oxy] acetate, a potent and selective secretory phospholipase A2 inhibitor: A new class of anti-inflammatory drugs, SPI.
Snyder DW; Bach NJ; Dillard RD; Draheim SE; Carlson DG; Fox N; Roehm NW; Armstrong CT; Chang CH; Hartley LW; Johnson LM; Roman CR; Smith AC; Song M; Fleisch JH
J Pharmacol Exp Ther; 1999 Mar; 288(3):1117-24. PubMed ID: 10027849
[TBL] [Abstract][Full Text] [Related]
24. Discrete roles of intracellular phospholipases A2 in human neutrophil cytotoxicity.
Mikami S; Aiboshi J; Kobayashi T; Kojima M; Morishita K; Otomo Y
J Trauma Acute Care Surg; 2015 Aug; 79(2):238-46. PubMed ID: 26218692
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and comparison of the antiinflammatory activity of manoalide and cacospongionolide B analogues.
De Rosa M; Giordano S; Scettri A; Sodano G; Soriente A; Pastor PG; Alcaraz MJ; Payá M
J Med Chem; 1998 Aug; 41(17):3232-8. PubMed ID: 9703468
[TBL] [Abstract][Full Text] [Related]
26. Phospholipase A2 superfamily members play divergent roles after spinal cord injury.
López-Vales R; Ghasemlou N; Redensek A; Kerr BJ; Barbayianni E; Antonopoulou G; Baskakis C; Rathore KI; Constantinou-Kokotou V; Stephens D; Shimizu T; Dennis EA; Kokotos G; David S
FASEB J; 2011 Dec; 25(12):4240-52. PubMed ID: 21868473
[TBL] [Abstract][Full Text] [Related]
27. Allelic association study between phospholipase A2 genes and bipolar affective disorder.
Meira-Lima I; Jardim D; Junqueira R; Ikenaga E; Vallada H
Bipolar Disord; 2003 Aug; 5(4):295-9. PubMed ID: 12895207
[TBL] [Abstract][Full Text] [Related]
28. Development of Potent and Selective Inhibitors for Group VIA Calcium-Independent Phospholipase A2 Guided by Molecular Dynamics and Structure-Activity Relationships.
Mouchlis VD; Limnios D; Kokotou MG; Barbayianni E; Kokotos G; McCammon JA; Dennis EA
J Med Chem; 2016 May; 59(9):4403-14. PubMed ID: 27087127
[TBL] [Abstract][Full Text] [Related]
29. Phospholipase A2 in chamber angle of normal eyes and patients with primary open angle glaucoma and exfoliation glaucoma.
Rönkkö S; Rekonen P; Kaarniranta K; Puustjarvi T; Teräsvirta M; Uusitalo H
Mol Vis; 2007 Mar; 13():408-17. PubMed ID: 17417602
[TBL] [Abstract][Full Text] [Related]
30. Secretory phospholipase A2 inhibitors and calmodulin antagonists as inhibitors of cytosolic phospholipase A2.
Hope WC; Chen T; Morgan DW
Agents Actions; 1993; 39 Spec No():C39-42. PubMed ID: 8273580
[TBL] [Abstract][Full Text] [Related]
31. The rat ovarian phospholipase A2 system: gene expression, cellular localization, activity characterization, and interleukin-1 dependence.
Kol S; Ruutiainen-Altman K; Ben-Shlomo I; Payne DW; Ando M; Adashi EY
Endocrinology; 1997 Jan; 138(1):322-31. PubMed ID: 8977420
[TBL] [Abstract][Full Text] [Related]
32. 2-Oxoamide inhibitors of phospholipase A2 activity and cellular arachidonate release based on dipeptides and pseudodipeptides.
Barbayianni E; Stephens D; Grkovich A; Magrioti V; Hsu YH; Dolatzas P; Kalogiannidis D; Dennis EA; Kokotos G
Bioorg Med Chem; 2009 Jul; 17(13):4833-43. PubMed ID: 19443224
[TBL] [Abstract][Full Text] [Related]
33. BMS-229724 is a tight-binding inhibitor of cytosolic phospholipase A2 that acts at the lipid/water interface and possesses anti-inflammatory activity in skin inflammation models.
Burke JR; Davern LB; Stanley PL; Gregor KR; Banville J; Remillard R; Russell JW; Brassil PJ; Witmer MR; Johnson G; Tredup JA; Tramposch KM
J Pharmacol Exp Ther; 2001 Jul; 298(1):376-85. PubMed ID: 11408565
[TBL] [Abstract][Full Text] [Related]
34. Assaying phospholipase A2 activity.
Leslie CC; Gelb MH
Methods Mol Biol; 2004; 284():229-42. PubMed ID: 15173620
[TBL] [Abstract][Full Text] [Related]
35. Synthesis of lipophilic 2-oxoamides based on gamma-aminobutyric and delta-aminovaleric analogues and their activity against phospholipase A2.
Moutevelis-Minakakis P; Neokosmidi A; Filippakou M; Stephens D; Dennis EA; Kokotos G
J Pept Sci; 2007 Oct; 13(10):634-41. PubMed ID: 17631670
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of phospholipase A2 reduces neurite outgrowth and neuronal viability.
Forlenza OV; Mendes CT; Marie SK; Gattaz WF
Prostaglandins Leukot Essent Fatty Acids; 2007 Jan; 76(1):47-55. PubMed ID: 17187973
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of allergic and non-allergic inflammation by phospholipase A2 inhibitors.
Tibes U; Vondran A; Rodewald E; Friebe WG; Schäfer W; Scheuer W
Int Arch Allergy Immunol; 1995; 107(1-3):432-4. PubMed ID: 7613203
[No Abstract] [Full Text] [Related]
38. Catalytic features, regulation and function of myocardial phospholipase A2.
McHowat J; Creer MH
Curr Med Chem Cardiovasc Hematol Agents; 2004 Jul; 2(3):209-18. PubMed ID: 15320787
[TBL] [Abstract][Full Text] [Related]
39. Novel inhibitor of phospholipase A2 with topical anti-inflammatory activity.
Tramposch KM; Steiner SA; Stanley PL; Nettleton DO; Franson RC; Lewin AH; Carroll FI
Biochem Biophys Res Commun; 1992 Nov; 189(1):272-9. PubMed ID: 1449483
[TBL] [Abstract][Full Text] [Related]
40. The effect of phospholipase A2 inhibitors on proliferation and apoptosis of murine intestinal cells.
Longo WE; Grossmann EM; Erickson B; Panesar N; Mazuski JE; Kaminski DL
J Surg Res; 1999 Jun; 84(1):51-6. PubMed ID: 10334889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
